Although preclinically evaluated as a cancer vaccine, with the proper soluble antigen this composition can potentially enhance response to other traditional vaccine targets.

About

Description Although traditionally viewed as an anti-infectious preventive measure, vaccine use has expanded to treating non-infectious diseases including cancer. Provenge (Dendreon) is currently the only FDA approved therapeutic vaccine at approximately $95,000 per treatment. Therapeutic vaccines in clinical trials are targeting glioblastoma, cervical, skin, head, neck, pancreatic, breast and lung cancer; as well as celiac disease and recurrent yeast infections from companies like GlaxoSmithkline, Rxi Pharmaceuticals and Pevion Vaccines. Advantages of the Invention  The invention, a recombinant vaccine composition, combines the beneficial traits of Fc tagged subunit and DNA vaccine paradigms, coupled with Virus-like particle aggregate antigen delivery to produce a robust immune response and induction of CD4 and CD8 T cells. Although preclinically evaluated as a cancer vaccine, with the proper soluble antigen this composition can potentially enhance response to other traditional vaccine targets.

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations